Study to investigate safety, tolerability, PK and PD response of SLN360 in subjects with elevated lipoprotein(a) (APOLLO) (NCT04606602)

AstraZeneca has provided a sponsorship grant towards this independent programme.

(Founding Partner)

Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.

Please login or create a FREE account to view this content